{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:06:34Z","timestamp":1787288794579,"version":"build-2736575974"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t Heidelberg der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recently, an autoantibody signature considered to be predictive of multiple sclerosis (MS) has been reported in an article by Zamecnik et al. published in Nature Medicine, which is characterized by immunoglobulin G (IgG) responses to peptides sharing the amino acid motif P-(SA)-x-(SGA)-R-(SN)-(LRKH). These results are highly important, all the more so as the same motif is present also in two proteins expressed by Epstein\u2013Barr virus (EBV), a pathogen that likely plays a key role in MS pathogenesis. However, clinically relevant autoantibody responses often target conformational epitopes, and peptides often differ from their corresponding proteins in terms of conformation. We were therefore interested in whether these findings can be reproduced at protein level and may thus play a role also in vivo. Here, we report findings from complementary experiments employing a microarray covering nearly 10,000 human full-length proteins and using serum and cerebrospinal fluid samples from patients with a histopathologically confirmed diagnosis of MS. Our data show that prominent IgG responses to full-length proteins bearing the P-(SA)-x-(SGA)-R-(SN)-(LRKH) motif can indeed be found in a substantial proportion of MS patients, although considerable inter-patient variability exists in both the type and number of individual responses. Notably, these IgG responses were more pronounced in patients with histopathologically defined pattern II MS (which is characterized by intralesional IgG and complement deposition) and pattern III MS than in patients with pattern I MS in our study. New motif-bearing candidate antigens identified in this study include RBMY2FP, CHMP2B, SRSF8 (SFRS2B), NUS1 (NgBR, Nogo-B receptor), and RTN2. Further studies investigating the diagnostic, pathophysiological, therapeutic, and prognostic implications of this antibody signature, as well as the potential role of cross-reactivity with EBV\u2014suggested by the presence of the motif of interest in both EBV BRRF2 and EBV envelope glycoprotein M\u2014are warranted and may significantly advance our understanding of MS.<\/jats:p>","DOI":"10.1007\/s00415-026-13661-z","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:50:24Z","timestamp":1775649024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An autoantibody signature predictive for multiple sclerosis: evidence at the protein level and association with histopathological lesion types"],"prefix":"10.1007","volume":"273","author":[{"given":"S.","family":"Jarius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ruprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. B.","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Br\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Wildemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"13661_CR1","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","volume":"375","author":"K Bjornevik","year":"2022","unstructured":"Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, Elledge SJ, Niebuhr DW, Scher AI, Munger KL, Ascherio A (2022) Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 375:296\u2013301","journal-title":"Science"},{"key":"13661_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.molimm.2019.09.014","volume":"114","author":"S Ferdous","year":"2019","unstructured":"Ferdous S, Kelm S, Baker TS, Shi J, Martin ACR (2019) B-cell epitopes: discontinuity and conformational analysis. Mol Immunol 114:643\u2013650","journal-title":"Mol Immunol"},{"key":"13661_CR3","doi-asserted-by":"publisher","first-page":"5088","DOI":"10.1073\/pnas.0914213107","volume":"107","author":"S Gnjatic","year":"2010","unstructured":"Gnjatic S, Ritter E, Buchler MW, Giese NA, Brors B, Frei C, Murray A, Halama N, Zornig I, Chen YT, Andrews C, Ritter G, Old LJ, Odunsi K, Jager D (2010) Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci U S A 107:5088\u20135093","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13661_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0214-9","volume":"6","author":"S Jarius","year":"2020","unstructured":"Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B (2020) Neuromyelitis optica. Nat Rev Dis Primers 6:85","journal-title":"Nat Rev Dis Primers"},{"key":"13661_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1742-2094-7-21","volume":"7","author":"S Jarius","year":"2010","unstructured":"Jarius S, Wandinger KP, Horn S, Heuer H, Wildemann B (2010) A new Purkinje cell antibody (anti-Ca) associated with subacute cerebellar ataxia: immunological characterization. J Neuroinflammation 7:21","journal-title":"J Neuroinflammation"},{"key":"13661_CR6","doi-asserted-by":"publisher","first-page":"W24","DOI":"10.1093\/nar\/gkx346","volume":"45","author":"MC Jespersen","year":"2017","unstructured":"Jespersen MC, Peters B, Nielsen M, Marcatili P (2017) BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res 45:W24\u2013W29","journal-title":"Nucleic Acids Res"},{"key":"13661_CR7","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/ana.20182","volume":"56","author":"CF Lucchinetti","year":"2004","unstructured":"Lucchinetti CF, Bruck W, Lassmann H (2004) Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol 56:308","journal-title":"Ann Neurol"},{"key":"13661_CR8","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200332","volume":"12","author":"F Pache","year":"2025","unstructured":"Pache F, Otto C, Wilken D, Lietzow T, Steinhagen K, Grage-Griebenow E, Schindler P, Niederschweiberer M, Wildemann B, Jarius S, Ruprecht K (2025) Broad analysis of serum and intrathecal antimicrobial antibodies in multiple sclerosis underscores unique role of Epstein-Barr virus. Neurol Neuroimmunol Neuroinflamm 12:e200332","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13661_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70430","volume":"32","author":"M Rodomonti","year":"2025","unstructured":"Rodomonti M, Pache F, Otto C, Schindler P, Eberspacher B, Geran R, Puthenparampil M, Gallo P, Wildemann B, Jarius S, Erdur H, Ruprecht K (2025) Retrospective in silico analysis of routine laboratory data supports a specific association of Epstein-Barr virus and multiple sclerosis. Eur J Neurol 32:e70430","journal-title":"Eur J Neurol"},{"key":"13661_CR10","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/1744666X.2021.1847642","volume":"16","author":"K Ruprecht","year":"2020","unstructured":"Ruprecht K (2020) The role of Epstein-Barr virus in the etiology of multiple sclerosis: a current review. Expert Rev Clin Immunol 16:1143\u20131157","journal-title":"Expert Rev Clin Immunol"},{"key":"13661_CR11","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1093\/brain\/awae244","volume":"148","author":"T Schneider-Hohendorf","year":"2025","unstructured":"Schneider-Hohendorf T, Wunsch C, Falk S, Raposo C, Rubelt F, Mirebrahim H, Asgharian H, Schlecht U, Mattox D, Zhou W, Dawin E, Pawlitzki M, Lauks S, Jarius S, Wildemann B, Havla J, Kumpfel T, Schrot MC, Ringelstein M, Kraemer M, Schwake C, Schmitter T, Ayzenberg I, Fischer K, Meuth SG, Aktas O, Hummert MW, Kretschmer JR, Trebst C, Kleffner I, Massey J, Muraro PA, Chen-Harris H, Gross CC, Klotz L, Wiendl H, Schwab N (2025) Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation. Brain 148:933\u2013940","journal-title":"Brain"},{"key":"13661_CR12","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s41591-024-02938-3","volume":"30","author":"CR Zamecnik","year":"2024","unstructured":"Zamecnik CR, Sowa GM, Abdelhak A, Dandekar R, Bair RD, Wade KJ, Bartley CM, Kizer K, Augusto DG, Tubati A, Gomez R, Fouassier C, Gerungan C, Caspar CM, Alexander J, Wapniarski AE, Loudermilk RP, Eggers EL, Zorn KC, Ananth K, Jabassini N, Mann SA, Ragan NR, Santaniello A, Henry RG, Baranzini SE, Zamvil SS, Sabatino JJ Jr., Bove RM, Guo CY, Gelfand JM, Cuneo R, von Budingen HC, Oksenberg JR, Cree BAC, Hollenbach JA, Green AJ, Hauser SL, Wallin MT, DeRisi JL, Wilson MR (2024) An autoantibody signature predictive for multiple sclerosis. Nat Med 30:1300\u20131308","journal-title":"Nat Med"},{"key":"13661_CR13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1021\/cc9900706","volume":"2","author":"JH Zhang","year":"2000","unstructured":"Zhang JH, Chung TD, Oldenburg KR (2000) Confirmation of primary active substances from high throughput screening of chemical and biological populations: a statistical approach and practical considerations. J Comb Chem 2:258\u2013265","journal-title":"J Comb Chem"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13661-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13661-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13661-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:44:12Z","timestamp":1779446652000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13661-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["13661"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13661-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.J. reports no competing interests. K.R. received research support from German Ministry of Education and Research, European Union (821283\u20132), Stiftung Charit\u00e9, Novartis, Merck Serono, Guthy-Jackson Charitable Foundation, and Arthur Arnstein Foundation and speaker\u2019s honoraria from Virion Serion and Novartis; none related to this study. I.M. reports personal fees from Sanofi, BiogenIdec, Bayer Healthcare, TEVA, Serono, Novartis, Genzyme, Roche, and grants from BiogenIdec, Genzyme, Sanofi; none related to this study. F.B.K. reports no competing interests. J.H. reports no competing interests. W.B. reports no competing interests. F.P. reports research support from Bayer, Novartis, Biogen, Teva, Sanofi-Aventis\/Genzyme, Alexion, and Merck Serono and research support from the German Research Council, Werth Stiftung of the City of Cologne, German Ministry of Education and Research, Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program, Guthy-Jackson Charitable Foundation, and NMSS; he also reports consulting fees as an associate editor for Neurology, Neuroimmunology & Neuroinflammation and as an academic editor for PloS ONE and consultant fees for Sanofi Genzyme, Biogen, MedImmune, Shire, and Alexion; he also reports speaker honoraria from Bayer, Novartis, Biogen, Teva, Sanofi-Aventis\/Genzyme, Merck Serono, Alexion, Chugai, MedImmune, and Shire; he is advisory board member for Novartis and MedImmune Scientific and hold stocks of Nocturne GmbH; all outside the submitted work. B.W. reported grants from the Deutsche Forschungsgemeinschaft, German Ministry of Education and Research, Baden-W\u00fcrttemberg Ministry for Science, Research and Art, Dietmar Hopp Foundation, Klaus Tschira Foundation, grants and personal fees from Merck and Novartis, and personal fees from Alexion, INSTAND e.V., Roche; none related to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All human studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}],"article-number":"257"}}